Reimagine their treatment journey with RUKOBIA
MANAGING ADULTS WITH MULTIDRUG-RESISTANT HIV-1 IS CHALLENGING1

REIMAGINE THEIR TREATMENT JOURNEY WITH RUKOBIA

A first-in-class attachment inhibitor

A first-in-class attachment inhibitor that directly targets HIV-1 to protect CD4+ T-cells2

Durable virologic suppression

Durable virologic suppression demonstrated over 5 years3

Robust CD4+ T-cell recovery

Robust and clinically meaningful CD4+T-cell recovery over 5 years3,4

RUKOBIA — A BREAKTHROUGH FIRST-IN-CLASS TREATMENT WITH A NOVEL MOA2

RUKOBIA, as part of an optimised background regimen, is the only therapy developed for people living with MDR HIV-1 clinically proven to offer virologic suppression and CD4+ T-cell recovery over 5 years.2,3

RUKOBIA INCLUDED IN EACS 2023 GUIDELINES

When a 2-3 drugs active regimen cannot be constructed with NRTI, NNRTI, PI/b and INSTI, a drug with a new mechanism of action such as fostemsavir can be selected to obtain such a 2-3 drugs active regimen.5

The many faces of people living with MDR HIV-1

See perspectives from people living with MDR HIV-1

View Now

First-in-class attachment inhibitor

Find out what makes RUKOBIA different from other ARV therapies6

Learn more

Durable 5-year efficacy

Explore the 5-year virologic suppression data for RUKOBIA for people living with MDR HIV-13

See the Data

Breaking news: 240-week BRIGHTE trial results

Dr. Mills shares an exciting announcement about the BRIGHTE 5-year data for RUKOBIA for people living with MDR HIV-13

Watch Video

ARV=antiretroviral; HIV-1=human immunodeficiency virus type-1; INSTI=integrase strand transfer inhibitor; MDR=multidrug-resistant; MOA=mechanism of action; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=nonnucleoside reverse transcriptase inhibitor; PI=protease inhibitor.

RUKOBIA, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.2

References:

  1. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. RUKOBIA Summary of Product Characteristics.
  3. Aberg J, Shepherd B, Wang M, et al. Poster presented at the 24th International AIDS Conference. 29 July – 2 August 2022. Montreal, Canada. EPB160.
  4. Llibre J, Aberg J, Walmsley S, et al. Poster present at the 19th European AIDS Conference (EAC). 18-21 October 2023. Warsaw, Poland. eP.A.093.
  5. EACS Guidelines. Version 12.0. October 2023.
  6. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.

PM-GBL-FST-WCNT-230008 | January 2025

Prescribing Information